UCSF Bladder Cancer Trial: Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
The combination of enfortumab vedotin (EV) with pembrolizumab and intensity‑modulated radiation therapy (IMRT) is being evaluated as a bladder‑sparing trimodality therapy for muscle‑invasive bladder cancer.
A phase Ib/II trial is assessing enfortumab vedotin (EV) combined with pembrolizumab and concurrent intensity‑modulated radiation therapy (IMRT) for patients with muscle‑invasive bladder cancer, aiming to determine dose, safety, and preliminary efficacy as a bladder‑sparing approach.
This combined modality may improve tumor control while preserving bladder function in patients unsuitable for standard radical cystectomy.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.